Tag: Ascensia Diabetes Care
In brief: MA enrollment update, Medline sales jump, Resmed distribution hub
February 27, 2026HME News Staff
WASHINGTON – Total Medicare Advantage enrollment continued to increase in 2026, but at a slower rate of growth than in previous years, according to a KFF analysis of enrollment data provided by the Centers for Medicare & Medicaid Services (CMS) on Feb. 13.
Just more than 35 million people are enrolled in Medicare Advantage as of Feb. 1, 2026, an increase of 1.1 million people since February 2025, representing 3% growth year over year. In 2025, enrollment increased 4%, which was a slower...
Bodlund moves to president and CEO at Ascensia
February 26, 2026HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care has appointed Peter Bodlun as president and CEO, effective April 1. Bodlund, who most recently served as Ascensia’s COO, succeeds Koichiro Sato, who will continue as COO of parent company PHC Group and head of PHC Group’s Diabetes Management business. The leadership transition reflects Ascensia’s sustained performance and continued focus on long-term growth, executional excellence, and sustained value creation, the company says. “Ascensia...
In brief: Sleep think tank, Medicaid managed care fraud, diabetes reorg
September 5, 2025HME News Staff
SAN DIEGO – Resmed has launched the Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health.
The company says the Sleep Institute partners with clinicians, researchers, policymakers and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions and elevate sleep as a global health priority.
“Sleep Institute reflects...
PHC to transfer Ascensia Diabetes Care to Senseonic, accelerate growth of Eversense
September 4, 2025HME News Staff
TOKYO – PHC Holdings Corp. has announced that subsidiary Ascensia Diabetes Care has signed a memorandum of understanding to transfer the commercial operations for Eversense Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings. The companies seek to unite Eversense R&D, manufacturing and commercial activities within Senseonics beginning Jan. 1, 2026, subject to a definitive agreement. The move would enable Eversense to accelerate growth and realize its full potential...
Senseonics, Ascensia hit sweet spot
March 3, 2025HME News Staff
PARSIPPANY, N.J. – Senseonics Holdings and Ascensia Diabetes Care have integrated SweetSpot with the Eversense 365 Continuous Glucose Monitoring (CGM) System in the U.S., providing endocrinology practices that partner with them the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients. SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services, including a virtual team...
Senseonics files for CE Mark
February 13, 2025HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care. “Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe,” said Tim Goodnow, president and CEO of Senseonics. “Given the success we have had to date with the U.S. launch, we look forward to the opportunity...
In brief: Hurricane waivers, NIV advocacy, CRT lobby
October 4, 2024HME News Staff
WASHINGTON – CMS will permit people with Medicare who have lost or had damage to their DMEPOS products because of Hurricane Helene to receive replacements of such items and services, according to a bulletin from AAHomecare.
Specifically, CMS waivers for Florida, Georgia, North Carolina, South Carolina, and Tennessee state that:
When DMEPOS is lost, destroyed, irreparably damaged, or otherwise rendered unusable, CMS is allowing DME MACs to have the flexibility to waive...
Ascensia launches Eversense 365
October 3, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched its Eversense 365 continuous glucose monitoring system, which received clearance from the U.S. Food and Drug Administration in September. “Eversense offers a completely differentiated CGM experience, overcoming many of the frustrations experienced with traditional, short-term CGMs, such as early failure, disruptive false alerts and skin irritation,” said Brian Hansen, president of CGM at Ascensia. “With only one CGM replacement...
Senseonics, Ascensia launch one-year CGM system
September 17, 2024HME News Staff
GERMANTOWN, Md., and PARSIPPANY, N.J. – Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system. “The approval of Eversense 365 represents a significant leap in CGM innovation,” said Tim Goodnow, PhD, president and CEO of Senseonics. “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides...
In brief: UHC’s new capitated arrangement, NCPA’s cyberattack request
May 3, 2024HME News Staff
MINNEAPOLIS – UnitedHealthcare has entered into a capitated arrangement with Synapse Health for standard DME in Georgia and North Carolina for its Medicare Advantage plan members enrolled in HMO and PPO plans.
The change, announced on UHC’s website on May 1, is effective Aug. 1.
DME providers will need to join the Synapse Health network to continue to provide standard DME for these plan members. Synapse Health will reach out to providers with details about joining...